carbendazim has been researched along with Colorectal Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Higa, AT; Jacobs, AT; McAllister, HA; Taylor, FR; Wales, CT | 1 |
Camden, JB; Davidson, K; Hammond, LA; Izbicka, E; Lawrence, R; Von Hoff, DD; Weitman, S | 1 |
2 other study(ies) available for carbendazim and Colorectal Neoplasms
Article | Year |
---|---|
ERK-dependent phosphorylation of HSF1 mediates chemotherapeutic resistance to benzimidazole carbamates in colorectal cancer cells.
Topics: Antineoplastic Agents; Benzimidazoles; Carbamates; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm; Heat Shock Transcription Factors; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nocodazole; Phosphorylation; Transcription Factors | 2015 |
Exploring the mechanisms of action of FB642 at the cellular level.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Carbamates; Cell Cycle; Cell Division; Colorectal Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genes, p53; Humans; Leukemia; Leukemia, Experimental; Male; Melanoma, Experimental; Mice; Neoplasm Proteins; Ovarian Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |